Urgent Call to Action: Improving Survival Rates for Bile Duct Cancer

Survival rates for cholangiocarcinoma, commonly known as bile duct cancer, remain alarmingly low, prompting a panel of leading experts to advocate for rapid advancements in diagnosis, treatment, and research. This rare but aggressive cancer, originating in the bile ducts, often progresses silently, leading to late-stage diagnoses and limited treatment options.

Understanding Bile Duct Cancer

Bile duct cancer develops in the small tubes that carry digestive fluid from the liver to the intestines. Symptoms can include jaundice, abdominal pain, weight loss, pale stools, and itching, but these are often mistaken for less serious conditions, delaying crucial diagnosis.

Grim Statistics and Rising Incidence

Approximately 3,000 people in England die from bile duct cancer annually, making it a particularly deadly cancer despite its relative rarity. A concerning trend shows a steady rise in incidence, even among younger adults, placing increasing strain on National Health Service (NHS) cancer services. Currently, up to 90% of patients are diagnosed too late for surgery, which remains the only potential cure. One-year survival rates hover around 25%.

Four Key Priorities for Improvement

An international consensus statement, published in Nature Reviews Gastroenterology & Hepatology and led by researchers from the European Network for the Study of Cholangiocarcinoma (ENSCCA), outlines four central priorities:

• Earlier Diagnosis: Increasing awareness of symptoms and streamlining referral pathways.
• Specialist Access: Expanding access to specialist surgery and cancer centers.
• Routine Molecular Testing: Implementing routine molecular (genetic) testing to personalize treatment plans.
• Increased Research Funding: Boosting research funding and supporting clinical trials.

The Importance of Molecular Testing

Molecular testing is critical for identifying targeted therapies and immunotherapies that can improve patient outcomes. However, these treatments are only effective when doctors understand the cancer’s specific genetic makeup.

Precision Medicine Initiatives

New clinical trials, such as the SAFIR-ABC10 trial sponsored by UCL and UCLH, are exploring precision medicine approaches. This trial aims to extend survival by tailoring treatments to the genetic profile of each patient’s tumor. The UK arm of the trial will recruit patients with intrahepatic, perihilar, or distal cholangiocarcinoma, or gallbladder cancer, and offer them one of seven anti-cancer therapies best matched to their tumor profile.

Expert Perspectives

Professor John Bridgewater, professor of medical oncology at the UCL Cancer Institute and consultant medical oncologist at UCLH, emphasizes the urgency of the situation. He notes that these cancers are becoming more common and that current standard of care typically results in only one year of survival after treatment begins. Professor Bridgewater specializes in gastrointestinal oncology, with a particular interest in biliary tract cancers. He leads the National Cancer Research Institute (NCRI) Study Group upper gastrointestinal malignancy and has contributed to landmark studies in gastrointestinal malignancy.

“Behind the statistics are real people and families facing devastating news. We urgently need more research, awareness and NHS investment to change outcomes,” adds Professor Bridgewater.

Ongoing Research and Future Directions

Research continues to focus on understanding the molecular characteristics of bile duct cancer and developing more effective targeted therapies. The Delphi consensus process involved 147 international opinion leaders from 35 countries, highlighting the global commitment to addressing this challenging disease.